Correlation Between Protagenic Therapeutics and Lixte Biotechnology

Can any of the company-specific risk be diversified away by investing in both Protagenic Therapeutics and Lixte Biotechnology at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Protagenic Therapeutics and Lixte Biotechnology into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Protagenic Therapeutics and Lixte Biotechnology Holdings, you can compare the effects of market volatilities on Protagenic Therapeutics and Lixte Biotechnology and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Protagenic Therapeutics with a short position of Lixte Biotechnology. Check out your portfolio center. Please also check ongoing floating volatility patterns of Protagenic Therapeutics and Lixte Biotechnology.

Diversification Opportunities for Protagenic Therapeutics and Lixte Biotechnology

-0.09

Correlation Coefficient

Protagenic Therapeutics  Lixte Biotechnology

Good diversification

The 3 months correlation between Protagenic and Lixte is -0.09. Overlapping area represents the amount of risk that can be diversified away by holding Protagenic Therapeutics and Lixte Biotechnology Holdings in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Lixte Biotechnology and Protagenic Therapeutics is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Protagenic Therapeutics are associated (or correlated) with Lixte Biotechnology. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Lixte Biotechnology has no effect on the direction of Protagenic Therapeutics i.e., Protagenic Therapeutics and Lixte Biotechnology go up and down completely randomly.

Pair Corralation between Protagenic Therapeutics and Lixte Biotechnology

Given the investment horizon of 90 days Protagenic Therapeutics is expected to generate 7.07 times less return on investment than Lixte Biotechnology. But when comparing it to its historical volatility, Protagenic Therapeutics is 1.1 times less risky than Lixte Biotechnology. It trades about 0.01 of its potential returns per unit of risk. Lixte Biotechnology Holdings is currently generating about 0.04 of returns per unit of risk over similar time horizon. If you would invest  200.00  in Lixte Biotechnology Holdings on September 18, 2024 and sell it today you would lose (1.00) from holding Lixte Biotechnology Holdings or give up 0.5% of portfolio value over 90 days.

Time Period	3 Months [change]
Direction	Moves Against
Strength	Insignificant
Accuracy	100.0%
Values	Daily Returns

Protagenic Therapeutics  vs.  Lixte Biotechnology Holdings

Protagenic Therapeutics

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days Protagenic Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of fairly strong forward indicators, Protagenic Therapeutics is not utilizing all of its potentials. The current stock price disturbance, may contribute to short-term losses for the investors.

Lixte Biotechnology

Risk-Adjusted Performance

2 of 100

Weak

Compared to the overall equity markets, risk-adjusted returns on investments in Lixte Biotechnology Holdings are ranked lower than 2 (%) of all global equities and portfolios over the last 90 days. In spite of comparatively weak basic indicators, Lixte Biotechnology unveiled solid returns over the last few months and may actually be approaching a breakup point.

Pair Trading with Protagenic Therapeutics and Lixte Biotechnology

The main advantage of trading using opposite Protagenic Therapeutics and Lixte Biotechnology positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Protagenic Therapeutics position performs unexpectedly, Lixte Biotechnology can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Lixte Biotechnology will offset losses from the drop in Lixte Biotechnology's long position.

The idea behind Protagenic Therapeutics and Lixte Biotechnology Holdings pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Idea Breakdown module to analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes.